Saneca Pharma secures Menarini Group contract
News Nov 10, 2016
Saneca Pharma has secured an agreement with Italian pharmaceutical company Menarini Group to deliver controlled release pellets for one of its products. As part of the five-year supply agreement, Saneca Pharma will be investing in its facility in Hlohovec, Slovakia, to increase the scale at which it can perform wurster coating of the pellets. The pellets are made by extrusion spheronisation.
The CDMO’s technology will be used to produce enteric coated pellets aimed at preventing dissolution in the stomach, while allowing dissolution in the small intestine. Commenting on the new contract, Anthony Sheehan, CEO at Saneca Pharma said: “We are pleased to be able to offer Menarini a responsive solution to help ensure the long term viability of its product.
“At Saneca Pharma, we have the breadth of technologies and expertise to handle challenging and complex pharmaceutical development and manufacturing projects. This new contract is just one example of how we can assist drug developers and manufacturers with specialist techniques to improve drug efficiency, delivery and patient compliance.”
Before securing the contract, Saneca Pharma demonstrated its pellet manufacturing capabilities to Menarini at a small scale using 100kg batch sizes. Following the investment at its plant, the CDMO will be able to handle significantly larger batch sizes. Francesco Nuzzolo, corporate director of manufacturing at Menarini Group said: “Saneca Pharma is the ideal partner for our pellet manufacturing needs as the team possess the experience along with the technology to successfully support us for these supplies.
“Saneca’s experts were extremely responsive and flexible from the outset of our relationship, demonstrating that they could manufacture enteric coated pellets in a cost-effective manner. We look forward to a successful, long-term partnership.” Based in western Slovakia, with close proximity to Vienna, Saneca Pharma develops and manufactures a variety of finished dosage forms, with strong capabilities in solids and semi-solids and specialist expertise in the development of opiate APIs and final dosage forms from farm to pharmacy.
Saneca Pharma has a proud’ big pharma’ heritage and combines a strong track record of consistent supply and stringent quality standards, with an impressive breadth of services, technical agility and dedicated experts to deliver responsive solutions.
Source: Story from Saneca Pharma. Please note: The content above may have been edited to ensure it is in keeping with Technology Networks' style and length guidelines.
XenoGesis and BioAscent Forge Alliance to Offer Enhanced Integrated Drug Discovery ServicesNews
XenoGesis and BioAscent Discovery Limited have announced a collaboration to offer an enhanced range of integrated drug discovery services, including medicinal chemistry, biology and DMPK.READ MORE
BioAscent Establishes Integrated Drug Discovery Services OfferingNews
Dr Phil Jones to join as new CSO to lead company’s extended capabilities in medicinal chemistry and in vitro biosciences.READ MORE
Lab Innovations returns to the NEC, Bimingham , UKNews
Save the date for the UK’s only lab-dedicated exhibition showcase!READ MORE
Comments | 0 ADD COMMENT
International Conference on Biobetters and Regulatory Affairs
Jun 27 - Jun 28, 2018